A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in India
← catalyst calendarNCT07157423 · readout in 371 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
64estimated
Sites
14
Country
India
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-26 | actual | When the study began enrolling |
| Primary completion | 2027-08-26 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-08-26 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Severe Postpartum Haemorrhage
Intervention
- Drug: Eptacog alfa (NovoSeven)
Primary outcome
what the primary-completion date above is the date OFNumber of thromboembolic events
measured From baseline (day 0) to end of study (day 30)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed